Hemispherx in hep C/HIV pact with Empire Health

12 July 2001

Hemispherx Biopharma, which focuses on the development of nucleic acidsto enhance antiviral defense systems, has entered into a strategic partnership with Empire Health Resources, the USA's leading privately-held health care management firm.

Under the agreement, Empire Health will provide the accrual and retention of all patients for Hemispherx' clinical trials of Ampligen (poly I: poly C12U), for the treatment of HIV, as well as protocols for the treatment of hepatitis C and the co-infection of hepatitis C virus and HIV. The therapy is currently in Phase IIb clinical trials.

William Carter, Hemispherx' chief executive, said that the growing prevalence of co-infection of HIV and hepatitis C among people with AIDS "has led to the development of a greater emphasis on the evolution of immune-based therapies."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.